Minor histocompatibility (H) antigens are the molecular targets of allo-immunity responsible both for the development of anti-tumor effects and for graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, despite their potential clinical use, our knowledge of human minor H antigens is largely limited by the lack of efficient methods of their characterization. Here we report a robust and efficient method of minor H gene discovery that combines whole genome association scans (WGAS) with cytotoxic T-lymphocyte (CTL) assays, in which the genetic loci of minor H genes recognized by the CTL clones are precisely identified using pooled-DNA analysis of immortalized lymphoblastoid cell lines with/without susceptibility to those CTLs. Using this method, we have successfully mapped two loci: one previously characterized (HMSD encoding ACC-6), and one novel. The novel minor H antigen encoded by the BCL2A1 was identified within a 26 kb linkage disequilibrium block on chromosome 15q25, which had been directly mapped by WGAS. The pool size required to identify these regions was no more than 100 individuals.
Introduction
Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been established as one of the most effective therapeutic options for hematopoietic malignancies 1 and also implicated as a promising approach for some solid cancers.
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Its major therapeutic benefits are obtained from allo-immunity directed against patients' tumor cells (graft-versus-tumor effects, GVT). However, the same kind of allo-immune reactions can also be directed against normal host tissues resulting in graft-versus-host disease, or GVHD. In HLA-matched transplants, both GVT and GVHD are initiated by the recognition of HLA-bound polymorphic peptides, or minor histocompatibility (H) antigens, by donor T cells.
Minor H antigens are typically encoded by dichotomous SNP alleles, and may potentially be targeted by allo-immune reactions if the donor and recipient are mismatched at the minor H loci. Identification and characterization of minor H antigens that are specifically expressed in hematopoietic tissues, but not in other normal tissues, could contribute to the development of selective anti-leukemic therapies, while minimizing unfavorable GVHD reactions, one of the most serious complications of allo-HSCT. 3, 4 Unfortunately, the total number of such useful minor H antigens that are currently molecularly characterized is still disappointingly small − including HA-1, 5 HA-2, 6 ACC-1 Y and ACC-2, 7 DRN-7, 8 ACC-6, 9 LB-ADIR-1F, 10 HB-1,
11
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From -4 -LRH-1, 12 and 7A7-PANE1 13 − limiting the number of patients eligible for such GVT-oriented immunotherapy.
Several techniques have been developed to identify novel minor H antigens targeted by CTLs generated from post transplant patients. Among these, linkage analysis based on the cytotoxicity of the CTL clones against panels of lymphoblastoid cell lines (B-LCLs) from large pedigrees was proposed as a novel genetic approach, 1 4 and has been successfully applied to identify novel minor H epitopes encoded by the BCL2A1 and P2RX5 genes. 7, 12 Nevertheless, the technology is still largely limited by its resolution; especially when large segregating families are not available. Linkage analysis using B-LCL panels from the Centre d'Etude du Polymorphism Humain (CEPH ) could only localize minor H loci within a range of 1.64 to 5.5 Mb which still contained 11-46 genes, 7 ,12,14 thus requiring additional selection procedures to identify the actual minor H genes.
On the other hand, clinically relevant minor H antigens might be associated with common polymorphisms within the human population, and therefore could be ideal targets of genetic association studies, considering recent advances of large-scale genotyping technologies and the assets of the International HapMap Project. 15, 16 In this alternative genetic approach using the extensive linkage disequilibrium (LD) found within the human genome, target loci
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From -5 -can be more efficiently localized within relatively small haplotype blocks without depending on limited numbers of recombination events, given the large number of genotyped genetic markers. 1 7 Moreover, since the presence of a target minor H allele in individual target cells can be determined by ordinary immunological assays using minor H antigen-specific CTL, the characterization of minor H antigens should be significantly more straightforward than identifying alleles associated with typical common complex diseases, for which typically weak to moderate genetic effects have been assumed.
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In this report, we describe a high-performance, cost-effective method for the identification of minor H antigens, in which whole genome association scans (WGASs) are performed based on single nucleotide polymorphism (SNP) array analysis of pooled DNA samples constructed from cytotoxicity-positive (CTX + ) and cytotoxicity-negative (CTX -) B-LCLs as determined by their susceptibility to CTL clones. Based on this method, termed WGA/CTL, we were able to map the previously characterized ACC-6 minor H locus to a 115 kb block containing only 4 genes, including HMSD. 9 Moreover, using the same approach, a novel minor H antigen encoded by the BCL2A1 gene was identified within a 26 kb block containing only BCL2A1 on chromosome 15q25. Surprisingly, the pool size required to identify these regions was no more than 100 individuals. Thus, this WGA/CTL method has significant potential to accelerate the discovery of minor H antigens that could be used in more
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Materials and methods

Cell isolation and cell cultures
This study was approved by the Institutional Review Board of Aichi Cancer Center and University of Tokyo according to the Declaration of Helsinki. All blood or tissue samples were collected after written informed consent. B-LCLs were derived from allo-HSCT donors, recipients, and healthy volunteers. B-LCLs were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate.
Generation of CTL lines and clones
CTL lines were generated from peripheral blood mononuclear cells (PBMC) obtained posttransplant by stimulation with irradiated (33 Gy) recipient PBMC harvested before HSCT, thereafter stimulated weekly in RPMI 1640 supplemented with 10% pooled human serum and 2 mM L-glutamine. IL-2 was added on days 1 and 5 after the second and third stimulations. CTL clones were isolated by standard limiting dilution and expanded as previously described. 7 CTL-1B9 was isolated from PBMC harvested on day 30 posttransplant from a patient receiving a marrow graft from his HLA-identical sibling (HLA For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -7 -A11, A24, B39, B51, Cw7, Cw14), and CTL-2A12 has been described recently. Cr for 2 h, and 1 × 10 3 target cells/well were mixed with CTL at the E:T ratio indicated in a standard 4-h cytotoxicity. All assays were performed at least in duplicate. Percent specific lysis was calculated as follows:
((Experimental cpm -Spontaneous cpm) / (Maximum cpm -Spontaneous cpm)) x100.
Immunophenotyping by enzyme-linked immunosorbent assay (ELISA)
B-LCL cells (20,000 per well) (which had been retrovirally transduced with restriction HLA cDNA for individual CTLs, if necessary) were plated in each well of 96-well round-bottomed plates, and corresponding CTL clones (10,000 per well) were added to each well. After overnight incubation at 37ºC, 50 µl of supernatant was collected and released IFN-γ was measured by standard ELISA.
Construction of pooled DNA and microarray experiments
Genomic DNA was individually extracted from immunophenotyped B-LCL. After
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -8 -DNA concentrations were measured and adjusted to 50 µ g/ml using the PicoGreen dsDNA Quantitation Reagent (Molecular Probes, Eugene, OR), the DNA specimens from CTX + and CTX -B-LCLs were separately combined to generate individual pools. DNA pools were analyzed in pairs using Affymetrix® GeneChip® SNP-genotyping microarrays (Affymetrix® Inc., Tokyo, Japan) according to the manufacturer's protocol, 19, 20 where two independent experiments were performed for each array type (For more detailed statistical analysis for generated microarray data, see Supplemental Methods).
Estimation of LD blocks
LD structures of the candidate loci were evaluated based on empirical data from the International Hap Map Project (http://www.hapmap.org/). 15 LD data for the relevant HapMap panels were downloaded from the HapMap web site and further analyzed using Haploview software (http://www.broad.mit.edu/mpg/haploview/) 21 .
Transfection of 293T cells and ELISA
Twenty thousand 293T cells retrovirally transduced with HLA-A*2402 were plated in each well of 96-well flat-bottomed plates, cultured overnight at 37ºC, then transfected with 0.12
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -9 -of plasmid containing full length BCL2A1 cDNA generated from either the patient or his donor using Trans IT-293 (Mirus, Madison, WI). B-LCLs of the recipient and his donor were used as positive and negative controls, respectively. Ten thousand CTL-1B9 cells were added to each well 20 h after transfection. After overnight incubation at 37ºC, 50 µl of supernatant was collected and IFN-γ was measured by ELISA.
SNP identification by direct sequencing
Complementary DNA prepared from B-LCLs was PCR amplified for the coding region of BCL2A1 using the following primers:
Sense: 5'-AGAAGATGACAGACTGTGAATTTGG -3' Antisense: 5'-TCAACAGTATTGCTTCAGGAGAG -3' PCR products were purified and directly sequenced with the same primer and BigDye
Terminator kit (ver. 3.1) by using ABI PRISM 3100 (Applied Biosystems, Foster City, CA).
Confirmatory SNP genotyping
Genotyping was carried out using fluorogenic 3'-minor groove binding (MGB) probes in a PCR assay. PCR was conducted in 10 µl reactions containing both allelic probes, For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -10 -500 nM each of the primers, 1× TaqMan Universal PCR Master Mix (Applied Biosystems), and 1 µl (100 ng) DNA. PCR cycling conditions were: pre-denature, 50°C for 2 minutes, 95°C for 10 minutes followed by 35 cycles of 92°C for 15 s and 60°C for 1 min in a GeneAmp PCR System 9700 (Applied Biosystems). The PCR products were analyzed on an ABI 7900HT with the aid of SDS 2.2 software (Applied Biosystems).
Epitope reconstitution assay
The candidate BCL2A1-encoded minor H epitope and its allelic counterpart (DYLQYVLQI) peptides were synthesized by standard Fmoc chemistry. On the other hand, positive association of the target minor H antigen with CTL-1B9 was detected in two independent loci: SNP rs1879894 at 15q25.1 in 250K NspI (Table 1, Figures 4A and 4B, and Supplemental Figure 5 ) and SNP rs1842353 at 8q12.3 in 50K HindIII (Table 1 and Supplemental Figure 3A ). We eventually focused on rs1879894, as it showed a much more significant genome-wide p value than SNP rs1842353 ( Table 1 ). In contrast to the CTL-2A12 case, where many mutually correlated SNPs around the most significant one created a broad peak in the statistic plots ( Table 3 ). The association was also detected when the references in the first and second pools were swapped (data not shown).
Identification of the minor H epitope recognized by CTL-1B9
The LD block containing SNP rs1879894 that was singled out from more than 500,000 SNP markers with two sets of DNA pools only encodes exon 1 of BCL2A1 ( Figure 3B ).
To our surprise, this was the region to which we had previously mapped an HLA-A24-restricted minor H antigen, ACC-1 Y . 7 We first confirmed that full length BCL2A1 cDNA cloned only from the recipient but not his donor could stimulate interferon-γ secretion from CTL-1B9 when transduced into donor B-LCL ( Figure 5A ), indicating that BCL2A1 is a bona fide gene encoding minor H antigen recognized by CTL-1B9. We next genotyped three nonsynonymous SNPs in the BCL2A1 exon 1 sequence ( Figure 3B ) and comparison was made between the genotypes and the susceptibility to CTL-1B9 of 9 HLA-A*2402 + B-LCLs, including ones generated from the recipient (from whom CTL-1B9 was established) and his donor. Susceptibility to CTL-1B9 correlated completely with the presence of guanine at SNP rs1138357 (nucleotide position 238, according to the mRNA sequence for NM_004049.2) and thymine at SNP rs1138358 (nucleotide position 299) ( Table 2 ), suggesting that the expression of the minor H epitope recognized by CTL-1B9 is controlled by either of these SNPs. We searched for nonameric amino acid sequences spanning the two SNPs using BIMAS software, 2 2 since most reported HLA-A*2402 binding peptides contain nine amino acid residues.
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Among these, a nonameric peptide, DYLQCVLQI (the polymorphic residue being underlined), has a predicted binding score of 75 and was considered as a candidate minor H epitope. As shown in Figure   5B , the DYLQCVLQI was strongly recognized by CTL-1B9, whereas its allelic counterpart, DYLQYVLQI, was not. Decameric peptide, QDYLQCVLQI, on the other hand, appeared to be weakly recognized; however it is likely that the nonameric form was actually being presented after N-terminal glutamine cleavage by aminopeptidase in the culture medium.
Because it was possible that the cystine might be cysteinylated, recognition of synthetic peptides DYLQCVLQI and cysteinylated DYLQC*VLQI were assayed using CTL-1B9.
Half-maximal lysis for the former was obtained at a concentration of 200 pM, whereas recognition of the latter was several-fold weaker ( Figure 5C ). Thus, we concluded that DYLQCVLQI defines the cognate HLA-A*2402-restricted CTL-1B9 epitope, now designated
. This incidentally provides a second example of products from both dichotomous SNP alleles being recognized as HLA-A*2402-restricted minor H antigens, the first example being the HB-1 minor H antigen. 24 Finally, real-time quantitative PCR revealed that T-cells C minor H antigen is indeed immunogenic ( Figure 5D ).
Discussion
Recent reports have unequivocally demonstrated that WGAS can be successfully used to identify common variants involved in a wide variety of human diseases. 25-27 Our report represents a novel application of WGAS to transplantation immunology, which provides a simple but robust method to fine map the genetic loci of minor H antigens whose expression is readily determined by standard immunophenotyping with CTL clones established from post-transplant patients.
The current WGA/CTL method has several desirable features that should contribute to the acceleration of minor H locus mapping. In comparing the method to those of linkage analysis and other non-genetic approaches, including direct peptide sequencing of chemically purified minor H antigens 5,6,10,13 and conventional expression cloning, 8,9,11 there are differences in terms of power, sensitivity, and specificity. Direct sequencing of minor H antigen peptide guarantees that the purified peptide is surely present on the cell surface as
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -17 -antigen, but it requires highly specialized equipment and personnel. Expression screening of cDNA libraries is also widely used and has become feasible with commercially available systems. However, it depends highly on the quality of the cDNA library and expression levels of the target genes. In addition, it often suffers from false positive results due to the forced expression of cDNA clones under a strong promoter. The current method of WGA/CTL genetically determines the relevant minor H antigen locus, not relying on highly technical protein chemistry utilizing specialized equipment, or repetitive cell cloning procedures. It is also not affected by the expression levels of the target antigens.
As a genetic approach, the current method based on genetic association has several advantages over conventional linkage analysis: the mapping resolution has been greatly improved from several Mb in the conventional linkage analysis to the average haplotype block size of less than 100kb, 17,25-27 usually containing a handful of candidate genes, compared to the dozens as typically found in linkage analysis. This means that the effort needed for the subsequent epitope mapping will be substantially reduced. In fact, the 115kb region identified for CTL-2A12 contains four genes compared to 38 genes as revealed by the previous linkage study (data not shown), and the candidate gene was uniquely identified within the 26kb region for CTL-1B9, for which linkage analysis had failed due to very rare segregating pedigrees Sensitivity of the microarray analysis seems to be very high when the target SNP has good proxy SNPs on the array, because we were able to correctly identify the single SNP correlated with the target of CTL-1B9 from more than 500,000 SNP markers. On the other hand, genome coverage of the microarray is definitely important. In our experiments on CTL-2A12, the association was successfully identified by the marker SNPs showing r 2 values of ~0.74 with the target locus of ACC-6. Since the GeneChip® 500K array set captures ~65% of all the HapMap phase II SNPs with more than 0.74 of r 2 (Nanya, et al. in press) and higher coverage will be obtained with the SNP 6.0 arrays having more than 1,000K SNP markers, these arrays can be satisfactorily used as platforms for the WGA/CTL method.
As shown in the current study, the intrinsic sensitivity and specificity of the WGA/CTL method in detecting associated SNPs were excellent. In other words, as long as 
-22 -allo-HSCT recipients has now been effectively doubled, accounting for 50% of transplants with HLA-A24 or 20% of all transplants performed in the Asian population. In conclusion, we have described a simple but powerful method for minor H mapping to efficiently accelerate the discovery of novel minor H antigens that will be needed to contribute to our understanding of the molecular mechanism of human allo-immunity.
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